This site is intended for health professionals only

Researchers call DES safety into question

teaser

The long-term safety and widespread use of drug-eluting stents (DESs) is a cause for concern and uncertainty, a study has concluded.

The review, just published in Heart, discusses available safety and efficacy data, factors influencing current practices and perceived value of DESs, and off-label use.

However, a related editorial comments that the balance of risk and benefit for DESs varies by patient subgroup.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

In those with on-label indications, the small excess of late stent thrombosis does not appear to compromise safety, and evidence backs use of DESs and administration of antiplatelet treatment as per original study protocols.

However, off-label use has raised concerns about late complications, so future studies should incorporate a range of uses to help decision-making in clinical practice.

The editorial concludes that “until such data become available, empirical extension of dual antiplatelet treatment to at least one year is justified”.

Heart

Take part in our prize-draw survey






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x